Steady-state captopril renography: continuous monitoring of the captopril-induced increase in 99mTc-MAG3 mean parenchymal transit time in renovascular hypertension. 1997

I E Esper, and M Chajari, and J Fonroget, and J P Neveu, and R Makdassi, and P Bailly, and A Fournier
Department of Biophysics and Nuclear Medicine, Centre Hospitalier Universitaire, Amiens, France.

Steady-state captopril renography (SSCR) is an original technique for assessing the captopril-induced increase in technetium-99m mercaptoacetyltriglycine (99mTc-MAG3) mean parenchymal transit time (MPTT) in kidneys affected with functional renal artery stenosis (RAS). The steady-state parenchymal activity achieved by constant infusion of 99mTc-MAG3 is directly linked to the MPTT of the radiopharmaceutical. This steady-state parenchymal activity was continuously monitored from 15 min before to 60 min after a single dose of captopril in order to detect possible disruption of the steady state. SSCR was performed in 11 hypertensive patients with unilateral RAS and in two with RAS of a solitary kidney before renal revascularization (RR). In four of these patients, an additional SSCR was performed after RR. Of the ten patients whose hypertension was cured or improved by RR, one presented an uninterpretable SSCR and six presented a positive SSCR on the affected side. Control SSCR performed in four of these six patients was bilaterally negative. SSCR was also bilaterally negative in the three patients who showed no blood pressure response to RR. These preliminary results tend to indicate that, in spite of the stability of pre- and post-captopril hydration and data acquisition conditions allowed by this steady-state technique, the sensitivity is lower than expected. However, the reason for the false-negative results does not seem to be inherent to SSCR.

UI MeSH Term Description Entries
D006978 Hypertension, Renovascular Hypertension due to RENAL ARTERY OBSTRUCTION or compression. Hypertension, Goldblatt,Goldblatt Syndrome,Goldblatt Hypertension,Renovascular Hypertension,Syndrome, Goldblatt
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008991 Monitoring, Physiologic The continuous measurement of physiological processes, blood pressure, heart rate, renal output, reflexes, respiration, etc., in a patient or experimental animal; includes pharmacologic monitoring, the measurement of administered drugs or their metabolites in the blood, tissues, or urine. Patient Monitoring,Monitoring, Physiological,Physiologic Monitoring,Monitoring, Patient,Physiological Monitoring
D011866 Radioisotope Renography Graphic tracing over a time period of radioactivity measured externally over the kidneys following intravenous injection of a radionuclide which is taken up and excreted by the kidneys. Renography,Radioisotope Renographies,Renographies,Renographies, Radioisotope,Renography, Radioisotope
D002216 Captopril A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline,Capoten,Lopirin,SQ-14,225,SQ-14,534,SQ-14225,SQ-14534,SQ 14,225,SQ 14,534,SQ 14225,SQ 14534,SQ14,225,SQ14,534,SQ14225,SQ14534
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity

Related Publications

I E Esper, and M Chajari, and J Fonroget, and J P Neveu, and R Makdassi, and P Bailly, and A Fournier
October 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
I E Esper, and M Chajari, and J Fonroget, and J P Neveu, and R Makdassi, and P Bailly, and A Fournier
March 1994, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih,
I E Esper, and M Chajari, and J Fonroget, and J P Neveu, and R Makdassi, and P Bailly, and A Fournier
May 1996, Annals of nuclear medicine,
I E Esper, and M Chajari, and J Fonroget, and J P Neveu, and R Makdassi, and P Bailly, and A Fournier
August 1990, Nuklearmedizin. Nuclear medicine,
I E Esper, and M Chajari, and J Fonroget, and J P Neveu, and R Makdassi, and P Bailly, and A Fournier
May 2006, Clinical nuclear medicine,
I E Esper, and M Chajari, and J Fonroget, and J P Neveu, and R Makdassi, and P Bailly, and A Fournier
June 1991, Ugeskrift for laeger,
I E Esper, and M Chajari, and J Fonroget, and J P Neveu, and R Makdassi, and P Bailly, and A Fournier
January 1987, Contributions to nephrology,
I E Esper, and M Chajari, and J Fonroget, and J P Neveu, and R Makdassi, and P Bailly, and A Fournier
August 1993, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin,
I E Esper, and M Chajari, and J Fonroget, and J P Neveu, and R Makdassi, and P Bailly, and A Fournier
May 1994, The Western journal of medicine,
I E Esper, and M Chajari, and J Fonroget, and J P Neveu, and R Makdassi, and P Bailly, and A Fournier
April 1990, Kaku igaku. The Japanese journal of nuclear medicine,
Copied contents to your clipboard!